BR0307319A - Forma de dosagem oral para liberação controlada de droga - Google Patents
Forma de dosagem oral para liberação controlada de drogaInfo
- Publication number
- BR0307319A BR0307319A BR0307319-0A BR0307319A BR0307319A BR 0307319 A BR0307319 A BR 0307319A BR 0307319 A BR0307319 A BR 0307319A BR 0307319 A BR0307319 A BR 0307319A
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- core
- oral dosage
- coating
- drug release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"FORMA DE DOSAGEM ORAL PARA LIBERAçãO CONTROLADA DE DROGA". Uma forma de dosagem oral compreendendo, (i) um núcleo capaz de sofrer erosão, cujo núcleo compreende uma base fraca farmaceuticamente ativa ou um seu sal ou solvato farmaceuticamente aceitável; e (ii) um revestimento capaz de sofrer erosão circundando o dito núcleo, cujo revestimento compreende uma ou mais aberturas estendendo-se substancialmente completamente através do dito revestimento mas não penetrando o dito núcleo e comunicando a partir do ambiente de uso ao dito núcleo; caracterizada em que liberação da base fraca farmaceuticamente ativa ou um seu sal ou solvato farmaceuticamente aceitável a partir da forma de dosagem ocorre através das ditas aberturas pela erosão do dito núcleo capaz de sofrer erosão e através de erosão do dito revestimento capaz de sofrer erosão sob condições de pH pré-determinadas; um processo para preparação de uma tal forma de dosagem e o uso de uma tal forma de dosagem em medicina.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0203297.7 | 2002-02-12 | ||
| GB0203297A GB0203297D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
| GB0203296.9 | 2002-02-12 | ||
| GBGB0203296.9A GB0203296D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
| GB0203298.5 | 2002-02-12 | ||
| GB0203298A GB0203298D0 (en) | 2002-02-12 | 2002-02-12 | Novel composition |
| PCT/GB2003/000594 WO2003068195A1 (en) | 2002-02-12 | 2003-02-12 | Oral dosage form for controlled drug release |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0307319A true BR0307319A (pt) | 2005-01-04 |
| BRPI0307319B1 BRPI0307319B1 (pt) | 2018-05-02 |
| BRPI0307319B8 BRPI0307319B8 (pt) | 2021-05-25 |
Family
ID=27738830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0307319A BRPI0307319B8 (pt) | 2002-02-12 | 2003-02-12 | forma de dosagem oral para liberação controlada de droga e processo para sua preparação |
Country Status (34)
| Country | Link |
|---|---|
| EP (1) | EP1474114B1 (pt) |
| JP (2) | JP2005526031A (pt) |
| KR (2) | KR20100086084A (pt) |
| CN (1) | CN100444833C (pt) |
| AP (1) | AP1736A (pt) |
| AR (1) | AR038417A1 (pt) |
| AT (1) | ATE455540T1 (pt) |
| AU (1) | AU2003245763B2 (pt) |
| BR (1) | BRPI0307319B8 (pt) |
| CA (1) | CA2475544A1 (pt) |
| CL (1) | CL2007003010A1 (pt) |
| CO (1) | CO5601025A2 (pt) |
| CY (1) | CY1109939T1 (pt) |
| DE (1) | DE60331041D1 (pt) |
| DK (1) | DK1474114T3 (pt) |
| EA (1) | EA008286B1 (pt) |
| EC (1) | ECSP045232A (pt) |
| ES (1) | ES2336319T3 (pt) |
| HK (1) | HK1072194A1 (pt) |
| IL (1) | IL163098A (pt) |
| IS (1) | IS2747B (pt) |
| MA (1) | MA27689A1 (pt) |
| MX (1) | MXPA04007794A (pt) |
| MY (1) | MY139719A (pt) |
| NO (1) | NO334453B1 (pt) |
| NZ (1) | NZ534152A (pt) |
| OA (1) | OA12770A (pt) |
| PE (1) | PE20030800A1 (pt) |
| PL (1) | PL206596B1 (pt) |
| PT (1) | PT1474114E (pt) |
| SI (1) | SI1474114T1 (pt) |
| TW (1) | TWI286079B (pt) |
| UY (1) | UY27660A1 (pt) |
| WO (1) | WO2003068195A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0120835D0 (en) | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
| GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| TW200517127A (en) * | 2003-08-07 | 2005-06-01 | Sb Pharmco Inc | Novel composition |
| GB0318824D0 (en) * | 2003-08-11 | 2003-09-10 | Glaxo Group Ltd | Novel composition |
| US7879354B2 (en) | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
| CN101410093A (zh) * | 2006-01-27 | 2009-04-15 | 欧兰德股份有限公司 | 包含弱碱性药物和有机酸的药物递送系统 |
| NZ570039A (en) * | 2006-01-27 | 2011-07-29 | Eurand Inc | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2150830B (en) * | 1983-12-05 | 1987-08-19 | Alza Corp | Drug dispenser |
| GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
| US6099859A (en) * | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| AR023700A1 (es) * | 1998-11-12 | 2002-09-04 | Smithkline Beecham Plc | Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina |
| KR100643833B1 (ko) * | 1998-11-12 | 2006-11-10 | 스미스클라인비이참피이엘시이 | 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물 |
| GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
-
2003
- 2003-02-10 MY MYPI20030447A patent/MY139719A/en unknown
- 2003-02-10 PE PE2003000145A patent/PE20030800A1/es active IP Right Grant
- 2003-02-11 UY UY27660A patent/UY27660A1/es not_active IP Right Cessation
- 2003-02-11 AR ARP030100422A patent/AR038417A1/es not_active Application Discontinuation
- 2003-02-11 TW TW092102772A patent/TWI286079B/zh not_active IP Right Cessation
- 2003-02-12 SI SI200331764T patent/SI1474114T1/sl unknown
- 2003-02-12 MX MXPA04007794A patent/MXPA04007794A/es active IP Right Grant
- 2003-02-12 OA OA1200400209A patent/OA12770A/en unknown
- 2003-02-12 EA EA200401071A patent/EA008286B1/ru not_active IP Right Cessation
- 2003-02-12 DK DK03739557.1T patent/DK1474114T3/da active
- 2003-02-12 AP APAP/P/2004/003087A patent/AP1736A/en active
- 2003-02-12 CN CNB038037378A patent/CN100444833C/zh not_active Expired - Lifetime
- 2003-02-12 PT PT03739557T patent/PT1474114E/pt unknown
- 2003-02-12 ES ES03739557T patent/ES2336319T3/es not_active Expired - Lifetime
- 2003-02-12 DE DE60331041T patent/DE60331041D1/de not_active Expired - Lifetime
- 2003-02-12 JP JP2003567378A patent/JP2005526031A/ja not_active Withdrawn
- 2003-02-12 PL PL371368A patent/PL206596B1/pl unknown
- 2003-02-12 NZ NZ534152A patent/NZ534152A/en not_active IP Right Cessation
- 2003-02-12 KR KR1020107015064A patent/KR20100086084A/ko not_active Application Discontinuation
- 2003-02-12 KR KR1020047012361A patent/KR101048925B1/ko active IP Right Grant
- 2003-02-12 BR BRPI0307319A patent/BRPI0307319B8/pt not_active IP Right Cessation
- 2003-02-12 EP EP03739557A patent/EP1474114B1/en not_active Expired - Lifetime
- 2003-02-12 WO PCT/GB2003/000594 patent/WO2003068195A1/en active Application Filing
- 2003-02-12 CA CA002475544A patent/CA2475544A1/en not_active Abandoned
- 2003-02-12 AT AT03739557T patent/ATE455540T1/de active
- 2003-02-12 AU AU2003245763A patent/AU2003245763B2/en not_active Expired
-
2004
- 2004-07-19 IL IL163098A patent/IL163098A/en active IP Right Grant
- 2004-08-05 IS IS7383A patent/IS2747B/is unknown
- 2004-08-09 CO CO04077244A patent/CO5601025A2/es not_active Application Discontinuation
- 2004-08-12 EC EC2004005232A patent/ECSP045232A/es unknown
- 2004-08-12 MA MA27822A patent/MA27689A1/fr unknown
- 2004-08-31 NO NO20043633A patent/NO334453B1/no not_active IP Right Cessation
-
2005
- 2005-04-25 HK HK05103523.5A patent/HK1072194A1/xx not_active IP Right Cessation
-
2007
- 2007-10-19 CL CL2007003010A patent/CL2007003010A1/es unknown
-
2010
- 2010-03-31 CY CY20101100304T patent/CY1109939T1/el unknown
- 2010-04-22 JP JP2010098906A patent/JP5279757B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0211317A (pt) | Sistema para a liberação controlada de uma droga por meio de retenção gástrica | |
| BRPI0409652A (pt) | tablete, embalagem farmacêutica, método de tratamento de doenças, e, método de preparação de um tablete | |
| AR037629A1 (es) | Formulaciones farmaceuticas que comprenden un derivado de platino | |
| BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
| ES2088312T3 (es) | Formulacion de liberacion controlada que contiene tramadol. | |
| SE9704869D0 (sv) | New pharmaceutical formulaton II | |
| NO20035210L (no) | 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer | |
| UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
| BRPI0307786B8 (pt) | composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água | |
| AR033688A1 (es) | Composicion parenteral reconstituible | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| BR0311414A (pt) | Agente terapêutico para uma bexiga hiperativa | |
| CY1109939T1 (el) | Εκ του στοματος χορηγουμενη μορφη δοσολογιας για ελεγχομενη αποδεσμευση φαρμακου | |
| ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
| ATE466008T1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen herstellung und pharmazeutische zusammensetzung, die diesen enthält | |
| BRPI0414305A (pt) | sistema de liberação de drogas por via oral | |
| NO20101070L (no) | Fremgangsmate til dosering av et medikament, samt doseringsform | |
| BRPI0412697A (pt) | composições farmacêuticas que apresentam um revestimento expansìvel | |
| BR0107899A (pt) | Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida | |
| BRPI0413419A (pt) | composição compreendendo rosiglitazone e um outro agente antidiabético | |
| AR026254A1 (es) | El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4 | |
| EA200300110A1 (ru) | Композиция элетриптана в виде частиц | |
| BR0111051A (pt) | Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente | |
| BR0307320A (pt) | Sistema de liberação osmótico | |
| CO4750645A1 (es) | Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: "PARA: INT. CL. A61K 9/44 Ipc: A61K 9/44 (2011.01), A61P 3/06 (2011.01), A61P 3/1 Free format text: PARA: INT. CL. A61K 9/44; A61P 3/06, 3/10, 9/12 Ipc: A61K 9/44 (2011.01), A61P 3/06 (2011.01), A61P 3/1 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 12/02/2023 |